Research programme: epigallocatechin gallate-based anticancer therapeutics - Viteava Pharmaceuticals

Drug Profile

Research programme: epigallocatechin gallate-based anticancer therapeutics - Viteava Pharmaceuticals

Alternative Names: EGCG-based anticancer therapeutics - Viteava; Green tea flavonoid-based anticancer therapeutics - Viteava; Proteasome endopeptidase complex inhibtors - Viteava; VEA-005; VEA-006; VPE-001; VPEA-002; VPEA-004

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; Hong Kong Polytechnic University; McGill University; University of South Florida; Wayne State University
  • Developer McGill University; Viteava Pharmaceuticals
  • Class Catechins; Flavonoids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Canada
  • 31 Jan 2014 Epigallocatechin gallate-based anticancer therapeutics is available for licensing as of 31 Jan 2014.
  • 31 Jan 2014 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top